Leonard Zehr, Author at BioTuesdays

This Week's Feature

Ocugen developing therapies for rare and underserved eye diseases

Shankar Musunuri, Chairman, CEO and Co-Founder Ocugen (NASDAQ:OCGN) is taking a multi-pronged approach to ophthalmology with a diversified pipeline that includes a breakthrough modifier gene therapy platform, novel...

February 25, 2020

Features

Genocea Biosciences: for the next generation of immunotherapies, targets matter

Chip Clark, President and CEO Using its unique ATLAS proprietary technology platform, Genocea Biosciences (NASDAQ:GNCA) is developing cancer immunotherapies that direct the body’s own tumor-fighting T-cells to the most...

February 18, 2020

Features

Stereotaxis focused on next generation robotic innovation in interventional medicine

David Fischel, Chairman and CEO Stereotaxis’ (NYSE American: STXS) launch in June 2019 of a next generation surgical robotic system, Genesis RMN, solidifies its commitment to innovation and collaboration as a stepping...

February 4, 2020

Features

Liminal BioSciences making headway in strategic transformation

Kenneth Galbraith, CEO Liminal BioSciences (NASDAQ, TSX:LMNL) is undergoing a significant strategic transformation to simplify its operations, achieve financial stability and focus R&D on small molecule therapeutics...

January 21, 2020

Features

iBio’s transformation driven by FastPharming System, 3D bioprinting materials and proprietary therapeutics

Tom Isett, Strategic Advisor and Board Member iBio (NYSE American:IBIO) is continuing its transition from a licensing business to a manufacturing services provider and developer of proprietary biologics. Central to the...

January 14, 2020

Features

BriaCell breast cancer program ready for partnering

Dr. Bill Williams, President and CEO BriaCell Therapeutics (OTCQB:BCTXD; TSXV:BCT) believes its Phase 2 clinical program in advanced breast cancer, which includes an ongoing combination study of its Bria-IMT with immune...

January 7, 2020

Features

Kane Biotech completes 12-month transformation; ready for robust growth

Kane Biotech (TSXV:KNE) has completed a major transformation during the past year, relaunching its animal health business, expanding into human health, raising non-dilutive financing, and hiring a new executive team...

December 10, 2019

Features

Squarex hopes to begin pivotal testing to prevent recurring cold sores in 2020

Closely-held Squarex will be seeking an end-of-Phase 2 meeting with the FDA in the first quarter of 2020 as a steppingstone for pivotal testing of its SQX770 topical treatment for the prevention of recurrent cold sores...

December 3, 2019

Features

Spring Bank heading into data-rich 2020

Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...

November 12, 2019

Features

Soricimed’s platform of unique peptides making waves in cancer and beyond

Closely-held Soricimed Biopharma has developed a first-in-class platform of synthetic peptides whose various targets include an “oncochannel” implicated in the development and progression of many forms of cancer.

October 29, 2019

Author - Leonard Zehr

Ocugen developing therapies for rare and underserved eye diseases

Genocea Biosciences: for the next generation of immunotherapies, targets matter

Stereotaxis focused on next generation robotic innovation in interventional medicine

Liminal BioSciences making headway in strategic transformation

iBio’s transformation driven by FastPharming System, 3D bioprinting materials and proprietary therapeutics

BriaCell breast cancer program ready for partnering

Kane Biotech completes 12-month transformation; ready for robust growth

Squarex hopes to begin pivotal testing to prevent recurring cold sores in 2020

Spring Bank heading into data-rich 2020

Soricimed’s platform of unique peptides making waves in cancer and beyond

Follow Us

General

More

Subscribe